Providing credible, evidence-based information about medical technologies, treatments, and models of care
Funded and managed by the Blue Shield of California Foundation for over 10 years, CTAF has long been recognized as one of the leading technology assessment programs in the country. In 2013, CTAF became a core program of the Institute for Clinical and Economic Review, and its approach has now been adapted to broaden stakeholder engagement and improve the application of CTAF products in practice and policy. Learn more »
CTAF has posted a new draft assessment report, "The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir in the Treatment of Chronic Hepatitis C Infection," which will be reviewed at a public meeting on March 10 in San Francisco. Read more »
Attend a Meeting
March 10, 2014
Mission Bay Conference Center at UCSF, San Francisco, CA
CTAF’s public deliberation of the evidence will provide clarity and guidance to clinicians, insurers, and patients confronted with decisions on how best to treat Hepatitis C. The meeting is timely given the recent introduction of new drugs and drug combinations with the potential to cure most patients faster and with fewer side effects than older treatments. More details on how to register and key dates for public comment.
Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.